MedTrace Logo

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients

NCT04370288 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-05-04

No results posted yet for this study

Summary

The severe acute respiratory syndrome caused by COVID-19 is now a global catastrophic event. Currently there is no approved drug or vaccine for the disease. Methylene blue (MB, oxidized form, blue color) has been used in many different areas of clinical medicine, ranging from malaria to orthopedics. Leucomethylene Blue (reduced form of MB, colorless) may be applied for the treatment of COVID-19 according to the scientific evidences.

Conditions

Interventions

DRUG

MCN (Methylene blue, vitamin C, N-acetyl cysteine)

A mixture of MCN will be injected to covid-19 patients.

Sponsors & Collaborators

  • Mashhad University of Medical Sciences

    lead OTHER

Principal Investigators

  • Daryoush Hamidi Alamdari, Ph.D · Mashhad University of Medical Sciences, Mashhad, Iran

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-19
Primary Completion
2020-09-20
Completion
2020-09-21

Countries

  • Iran

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370288 on ClinicalTrials.gov